小分子抑制剂的进化Mycobacterium结核病 门宁生物合成
Pankaj Sharma1, Quan Jiang1, Shao-Gang Li1
1Department of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, Newark, New Jersey 07103, United States.
Journal of medicinal chemistry
|March 4, 2025
概括
研究人员优化了JSF-2911,一个MenG酶抑制剂,创造了针对Mycobacterium结核病的新药. 像JSF-4898这样的新化合物显示出强度和疗效的提高,为结核病治疗提供了一个有前途的战略.
科学领域:
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
- 结核病研究 结核病研究
背景情况:
- 对于抗击Mycobacterium tuberculosis (M. 结核病) 感染的新药物存在着迫切的需要.
- 以前的研究针对的是menaquinone生物合成途径中的MenG酶.
研究的目的:
- 为了优化二氨基胺JSF-2911,解决其代谢不稳定性和低体外功效.
- 开发用于治疗结核病的新型MenG酶抑制剂.
主要方法:
- 击中进化运动,涉及对JSF-2911的氨基基结构的修改.
- 由此产生的类似物对生物活性和类似药物的特性进行了广泛的分析.
- 在感染M.结核病的小鼠模型中评估化合物的疗效.
主要成果:
- 优化的类似物,JSF-4536和JSF-4898,表现出对M.结核病的微小度最小抑制度 (MIC) 值.
- 在小鼠中,JSF-4536和JSF-4898证明了改善的代谢稳定性,水溶性和药用动力学特征.
- 在M.结核病感染的亚急性小鼠模型中,JSF-4898增强了瑞芬素的疗效.
结论:
- 优化的MenG抑制剂显示出作为针对M.结核病的新疗法药物的显著潜力.
- 需要进一步开发MenG抑制剂,以建立结核病的新治疗策略.
- 这些发现支持继续探索menaquinone途径作为抗结核病药物发现的目标.
相关概念视频
Enzyme Inhibition
77.7K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.7K
Drug Discovery: Overview
7.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.3K
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Enzymes
80.4K
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
80.4K
Introduction to Enzymes
17.0K
The use of enzymes by humans dates to 7000 BCE. Humans first used enzymes to ferment sugars and produce alcohol without knowing that this was an enzyme-catalyzed reaction. Wilhelm Kuhne coined the term 'enzyme' in 1877 from the Greek words ‘en’ meaning ‘in’ or ‘within’ and ‘zyme’ meaning ‘yeast.’
Most enzymes are proteins that speed up biochemical reactions without being consumed. Enzymes contain one or more active sites that...
Most enzymes are proteins that speed up biochemical reactions without being consumed. Enzymes contain one or more active sites that...
17.0K
Structure-Activity Relationships and Drug Design
480
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
480


